drugset / Trial / NCT03850587

Clinical Trial of YYC301 for Treatment of Osteoarthritis of the Knee

NCT03850587

RandomizedParallel-groupDouble-blindTreatment

Summary

A Multi-center, Double-blinded, Randomized, Active-controlled, Parallel Design, phaseII Study to Investigate the Efficacy and Safety of YYC301 in Subject With Knee Osteoarthritis

Timeline

Start
2018-08-30
Primary completion
2020-05-12
Completion
2020-09-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 200 mg
Subject Tramadol Other / unclassified 37.5 mg
Subject Tramadol Other / unclassified 75 mg
Subject Tramadol Other / unclassified 150 mg

Indications